Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case–Control Study in a Mission Hospital, Ghana

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL

Health Science Reports Pub Date : 2025-04-10 DOI:10.1002/hsr2.70642

Samuel Kwasi Appiah, Bosomtwi Boateng, Charles Nkansah, Bismark Nantomah, Sibiri Ballu, Gabriel Abbam, Samira Daud, Gifty Yambor Yenpiini, Ethel Akabawon Abagulum, Felix Osei-Boakye, Christopher Nkrumah, Michael Asamoah Gyamfi, Eric Antwi Osei Kwadwo, Yussif Adams, Simon Bannison Bani, Moses Banyeh, Adams Abubakari Sadick, Haajaratu Zama Alhassan, Solomon Yeboah, Charles A. Derigubah, Ejike Felix Chukwurah

{"title":"Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case–Control Study in a Mission Hospital, Ghana","authors":"Samuel Kwasi Appiah, Bosomtwi Boateng, Charles Nkansah, Bismark Nantomah, Sibiri Ballu, Gabriel Abbam, Samira Daud, Gifty Yambor Yenpiini, Ethel Akabawon Abagulum, Felix Osei-Boakye, Christopher Nkrumah, Michael Asamoah Gyamfi, Eric Antwi Osei Kwadwo, Yussif Adams, Simon Bannison Bani, Moses Banyeh, Adams Abubakari Sadick, Haajaratu Zama Alhassan, Solomon Yeboah, Charles A. Derigubah, Ejike Felix Chukwurah","doi":"10.1002/hsr2.70642","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aim</h3>\n \n <p>Currently, available evidence suggests prostate-specific antigen (PSA) is highly sensitive but poorly specific for prostate cancer detection in symptomatic patients and those with lower urinary tract symptoms. Serum ferritin and hepcidin, which are implicated in the pathogenesis of prostate cancers, may complement the diagnostic value of PSA. This study explored the correlation of serum PSA with ferritin and hepcidin as new and complementary diagnostic biomarkers for prostate disease.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This hospital-based case–control study was conducted at Methodist Hospital, Wenchi, with 90 participants. Venous blood sample was taken for complete blood count, PSA, ferritin, and hepcidin measurements using Mindray automated hematology analyzer and ELISA, respectively. Data were analyzed with SPSS version 27, and <i>p</i> < 0.05 was considered statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Serum PSA levels were significantly higher among the Prostate Cancer patients compared to BPE patients [32.1 (18.2–47.6) vs. 18.3 (12.2–0.6), <i>p</i> < 0.001]. Levels of serum ferritin and hepcidin were found to be significantly higher in PCa patients compared to BPE and controls <i>(p</i> < 0.001). Serum PSA of prostate disease patients showed a strong positive correlation with levels of ferritin (<i>r</i> = 0.739, <i>p</i> < 0.001) but moderately correlated with serum hepcidin levels (<i>r</i> = 0.670, <i>p</i> < 0.001). Serum ferritin was found to be an excellent diagnostic marker for prostate cancer (AUC = 0.972, <i>p</i> < 0.001) and BPE (AUC = 0.900, <i>p</i> < 0.001). Serum hepcidin was a better marker for PCa (AUC = 0.911) but a poor BPE (AUC = 0.664, <i>p</i> = 0.023). Significant reduction in the levels of Hb, RBC, MCHC, and HCT but higher counts of TWBC and RDW-CV were observed in patients with prostate cancers compared to those with BPE and the normal control group <i>(p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>High levels of serum ferritin and hepcidin significantly correlated directly with increased serum total PSA levels and could play a valuable role to complement the noninvasive total PSA to improve diagnostic accuracy.</p>\n </section>\n </div>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"8 4","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hsr2.70642","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aim

Currently, available evidence suggests prostate-specific antigen (PSA) is highly sensitive but poorly specific for prostate cancer detection in symptomatic patients and those with lower urinary tract symptoms. Serum ferritin and hepcidin, which are implicated in the pathogenesis of prostate cancers, may complement the diagnostic value of PSA. This study explored the correlation of serum PSA with ferritin and hepcidin as new and complementary diagnostic biomarkers for prostate disease.

Methods

This hospital-based case–control study was conducted at Methodist Hospital, Wenchi, with 90 participants. Venous blood sample was taken for complete blood count, PSA, ferritin, and hepcidin measurements using Mindray automated hematology analyzer and ELISA, respectively. Data were analyzed with SPSS version 27, and p < 0.05 was considered statistically significant.

Results

Serum PSA levels were significantly higher among the Prostate Cancer patients compared to BPE patients [32.1 (18.2–47.6) vs. 18.3 (12.2–0.6), p < 0.001]. Levels of serum ferritin and hepcidin were found to be significantly higher in PCa patients compared to BPE and controls (p < 0.001). Serum PSA of prostate disease patients showed a strong positive correlation with levels of ferritin (r = 0.739, p < 0.001) but moderately correlated with serum hepcidin levels (r = 0.670, p < 0.001). Serum ferritin was found to be an excellent diagnostic marker for prostate cancer (AUC = 0.972, p < 0.001) and BPE (AUC = 0.900, p < 0.001). Serum hepcidin was a better marker for PCa (AUC = 0.911) but a poor BPE (AUC = 0.664, p = 0.023). Significant reduction in the levels of Hb, RBC, MCHC, and HCT but higher counts of TWBC and RDW-CV were observed in patients with prostate cancers compared to those with BPE and the normal control group (p < 0.05).

Conclusion

High levels of serum ferritin and hepcidin significantly correlated directly with increased serum total PSA levels and could play a valuable role to complement the noninvasive total PSA to improve diagnostic accuracy.

Abstract Image

查看原文本刊更多论文

血清铁蛋白和Hepcidin作为前列腺疾病的补充生物标志物的诊断意义：加纳一家教会医院的前瞻性病例对照研究

背景和目的目前，已有证据表明前列腺特异性抗原（PSA）对有症状的前列腺癌患者和有下尿路症状的前列腺癌检测具有高度敏感性，但特异性较差。血清铁蛋白和hepcidin与前列腺癌的发病机制有关，可以补充PSA的诊断价值。本研究探讨了血清PSA与铁蛋白和hepcidin作为前列腺疾病新的补充诊断生物标志物的相关性。方法在温池市卫理公会医院进行以医院为基础的病例对照研究，共90例。静脉血分别采用迈瑞全自动血液学分析仪和ELISA检测全血细胞计数、PSA、铁蛋白和hepcidin。数据采用SPSS 27版分析，p <； 0.05为差异有统计学意义。结果前列腺癌患者血清PSA水平明显高于BPE患者[32.1（18.2-47.6）比18.3 (12.2-0.6),p < 0.001]。与BPE和对照组相比，PCa患者血清铁蛋白和hepcidin水平显著升高（p < 0.001）。前列腺疾病患者血清PSA与铁蛋白水平呈强正相关（r = 0.739, p < 0.001），与hepcidin水平呈中度相关（r = 0.670, p < 0.001）。血清铁蛋白是诊断前列腺癌（AUC = 0.972, p < 0.001）和BPE （AUC = 0.900, p < 0.001）的良好指标。血清hepcidin是较好的前列腺癌标志物（AUC = 0.911），而BPE较差（AUC = 0.664, p = 0.023）。与BPE患者和正常对照组相比，前列腺癌患者Hb、RBC、MCHC和HCT水平显著降低，但TWBC和RDW-CV计数较高（p < 0.05）。结论血清铁蛋白和hepcidin水平升高与血清总PSA水平升高直接相关，可作为无创总PSA的补充，提高诊断准确性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊